KEY POINTS
- This retrospective single-center case series included six patients with diffuse hepatic metastases from advanced solid tumors, including three lung cancers, two gastrointestinal cancers and one cervical cancer. All had progressed after at least one systemic treatment line; five had previously received immune checkpoint inhibitors, while one was immunotherapy-naive.
- The entire liver was irradiated using 7 Gy in five daily fractions of 1.4 Gy, delivered with 3D conformal RT or IMRT. PD-1 inhibitor treatment began the day after completion of irradiation and was generally administered every three weeks, with drug selection and subsequent treatment modified according to clinical circumstances.
- Radiological response assessment reported two complete responses and two partial responses, producing an objective response rate of 66.7% (4/6). Responses occurred across different primary tumor types, but this extremely small heterogeneous cohort cannot establish the relative contribution of low-dose irradiation and immune checkpoint inhibition.
- Four of six patients experienced symptomatic improvement, including relief of fatigue, anorexia or abdominal discomfort, while tumor markers declined substantially in three patients. Reported reductions included 92.8% in CEA, 91.4% in Pro-GRP, and 78.2% in CEA in individual responders, without standardized comparative quality-of-life assessment.
- One patient demonstrated regression of mediastinal lymph nodes outside the irradiated liver, described by the investigators as a possible abscopal effect. However, systemic immunotherapy was administered immediately after RT and subsequent treatments were heterogeneous, making it impossible to attribute this extrahepatic response specifically to radiation-induced immune activation.
- Median follow-up was 7.5 months, with individual follow-up ranging from 1 to 18 months. At the analysis cutoff, five patients had died and one remained alive; two discontinued further systemic therapy for personal or financial reasons, limiting assessment of treatment durability and long-term toxicity.
- No grade ≥3 adverse events were considered definitively attributable to the combination during treatment, but one patient developed grade 3 fatigue, abdominal pain and liver biochemical abnormalities, while another experienced grade 4 transaminitis during subsequent progression. Disease progression was considered the more likely explanation, although treatment contribution could not be excluded; these events and incomplete follow-up prevent firm safety conclusions.
CLINICAL TAKEAWAY
Low-dose whole-liver RT combined with PD-1 blockade is an interesting investigational strategy for patients with diffuse, treatment-refractory hepatic metastases, particularly where conventional ablative treatment is infeasible. The apparent response rate is striking but comes from only six uncontrolled cases, and neither an independent radiation effect nor clinically meaningful treatment synergy has been demonstrated; the regimen should not be considered an established salvage treatment.